A tumour that secretes glucagon-like peptide-1 and somatostatin in a patient with reactive hypoglycaemia and diabetes

Jeannie F. Todd, S. A. Stanley, C. A. Roufosse, A. E. Bishop, B. Khoo, S. R. Bloom, K. Meeran

Research output: Contribution to journalArticlepeer-review

41 Scopus citations

Abstract

Glucagon-like peptide 1 (GLP-1), an insulinotropic hormone normally synthesised in the intestinal mucosa and released in response to a meal, is essential for normal glucose homoeostasis. There is much interest in the use of GLP-1 to treat diabetes, since the risk of hypoglycaemia is thought to be low. We report an instance of a 45-year-old woman with a GLP-1 and somatostatin secreting neuroendocrine tumour who presented with reactive hypoglycaemia and hyperglycaemia, but who was subsequently cured by surgery. This case, of a neuroendocrine tumour secreting GLP-1 and causing reactive hypoglycaemia, indicates a potential adverse effect of GLP-1 therapy for diabetes.

Original languageEnglish
Pages (from-to)228-230
Number of pages3
JournalThe Lancet
Volume361
Issue number9353
DOIs
StatePublished - 18 Jan 2003
Externally publishedYes

Fingerprint

Dive into the research topics of 'A tumour that secretes glucagon-like peptide-1 and somatostatin in a patient with reactive hypoglycaemia and diabetes'. Together they form a unique fingerprint.

Cite this